Advanced search
1 file | 2.36 MB

Immunoengineering through cancer vaccines - A personalized and multi-step vaccine approach towards precise cancer immunity

Author
Organization
Abstract
During the last decade anti-tumor immune-therapy has opened novel opportunities to efficiently combat cancer progression. The introduction of DC-and CAR T-cell based therapies as well as the successful application of antibody-based inhibitor of immune checkpoints (CTLA-4, PD1 and PDL1) have boosted the field and led to an overall benefit for many patients. In situ cancer vaccination is an attractive strategy to further improve the therapeutic outcome, especially towards a more personalized and individually tailored immune response against the patient's mutanome. Nanoparticle-based delivery platforms can assist in combination treatments e.g. with multiple immune stimulatory signales (PAMPs and DAMPs) to increase the probability of evoking broader and all-embracing cytotoxic and memory T-cell responses. In this review, various approaches and hurdles of cancer vaccination are discussed including the beneficial contributions of the thriving field of nanoparticle design and functionalization, which may further boost the development of cancer immunotherapeutics.
Keywords
MHC CLASS-I, REGULATORY T-CELLS, TUMOR-ASSOCIATED MACROPHAGES, TARGETING, DENDRITIC CELLS, DEATH-LIGAND 1, RESISTANT PROSTATE-CANCER, LOW-DOSE, CHEMOTHERAPY, INDOLEAMINE 2, 3-DIOXYGENASE, SUPPRESSOR-CELLS, ANTIGEN, PRESENTATION

Downloads

  • 1-s2.0-S0168365918305285-main.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 2.36 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Lybaert, Lien, Karim Vermaelen, Bruno G. De Geest, and Lutz Nuhn. 2018. “Immunoengineering Through Cancer Vaccines - A Personalized and Multi-step Vaccine Approach Towards Precise Cancer Immunity.” Journal of Controlled Release 289: 125–145.
APA
Lybaert, L., Vermaelen, K., De Geest, B. G., & Nuhn, L. (2018). Immunoengineering through cancer vaccines - A personalized and multi-step vaccine approach towards precise cancer immunity. JOURNAL OF CONTROLLED RELEASE, 289, 125–145.
Vancouver
1.
Lybaert L, Vermaelen K, De Geest BG, Nuhn L. Immunoengineering through cancer vaccines - A personalized and multi-step vaccine approach towards precise cancer immunity. JOURNAL OF CONTROLLED RELEASE. Amsterdam: Elsevier Science Bv; 2018;289:125–45.
MLA
Lybaert, Lien et al. “Immunoengineering Through Cancer Vaccines - A Personalized and Multi-step Vaccine Approach Towards Precise Cancer Immunity.” JOURNAL OF CONTROLLED RELEASE 289 (2018): 125–145. Print.
@article{8601282,
  abstract     = {During the last decade anti-tumor immune-therapy has opened novel opportunities to efficiently combat cancer progression. The introduction of DC-and CAR T-cell based therapies as well as the successful application of antibody-based inhibitor of immune checkpoints (CTLA-4, PD1 and PDL1) have boosted the field and led to an overall benefit for many patients. In situ cancer vaccination is an attractive strategy to further improve the therapeutic outcome, especially towards a more personalized and individually tailored immune response against the patient's mutanome. Nanoparticle-based delivery platforms can assist in combination treatments e.g. with multiple immune stimulatory signales (PAMPs and DAMPs) to increase the probability of evoking broader and all-embracing cytotoxic and memory T-cell responses. In this review, various approaches and hurdles of cancer vaccination are discussed including the beneficial contributions of the thriving field of nanoparticle design and functionalization, which may further boost the development of cancer immunotherapeutics.},
  author       = {Lybaert, Lien and Vermaelen, Karim and De Geest, Bruno G. and Nuhn, Lutz},
  issn         = {0168-3659},
  journal      = {JOURNAL OF CONTROLLED RELEASE},
  language     = {eng},
  pages        = {125--145},
  publisher    = {Elsevier Science Bv},
  title        = {Immunoengineering through cancer vaccines - A personalized and multi-step vaccine approach towards precise cancer immunity},
  url          = {http://dx.doi.org/10.1016/j.jconrel.2018.09.009},
  volume       = {289},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: